Patents by Inventor Henry A. Lardy

Henry A. Lardy has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Use of &Dgr;5-androstene-3&bgr;ol-7,17-dione in the treatment of lupus erythematosus
    Patent number: 6593316
    Abstract: Lupus erythematosus can be treated by administering therapeutic amounts of &Dgr;5-androstene-3&bgr;-ol-7,17-dione and metabolizable precursors thereof, such as &Dgr;5-androstene-3&bgr;-acetoxy-7,17-dione, which are readily metabolized in vivo to &Dgr;5-androstene-3&bgr;-ol-7,17-dione but are not appreciably metabolizable in vivo to androgens, estrogens or dehydroepiandrosterone. Such treatment can be prophylactic, ameliorative or curative in nature.
    Type: Grant
    Filed: March 22, 2002
    Date of Patent: July 15, 2003
    Inventors: Henry A. Lardy, Charles E. Weeks
  • Blood cell deficiency treatment method
    Publication number: 20030083231
    Abstract: The invention relates to the use of compounds to treat a number of conditions, such as thrombocytopenia, neutropenia or the delayed effects of radiation therapy. Compounds that can be used in the invention include methyl-2,3,4-trihydroxy-1-O-(7,17-dioxoandrost-5-ene-3&bgr;-yl)-&bgr;-D-glucopyranosiduronate, 16&agr;,3&agr;-dihydroxy-5&agr;-androstan-17-one or 3,7,16,17-tetrahydroxyandrost-5-ene, 3,7,16,17-tetrahydroxyandrost-4-ene,3,7,16,17-tetrahydroxyandrost-1-ene or 3,7,16,17-tetrahydroxyandrostane that can be used in the treatment method.
    Type: Application
    Filed: March 1, 2002
    Publication date: May 1, 2003
    Inventors: Clarence N. Ahlem, Christopher Reading, James Frincke, Dwight Stickney, Henry A. Lardy, Padma Marwah, Ashok Marwah, Patrick T. Prendergast
  • Memory by the administration of &Dgr;5-androstene-3&bgr;-ol-7,17-dione and 3&bgr; esters
    Patent number: 6489313
    Abstract: The memory of a healthy mammal and the memory of a mammal with age impaired memory can be improved by administering an effective amount of &Dgr;5-Androstene-3&bgr;-ol-7,17-dione and 3&bgr; esters thereof.
    Type: Grant
    Filed: November 1, 2000
    Date of Patent: December 3, 2002
    Assignee: Humanetics Corporation
    Inventors: Henry A. Lardy, Jennifer Y. Shi
  • Use of delta5-androstene-3beta ol-7,17-dione in the treatment of lupus erythematosus
    Publication number: 20020160989
    Abstract: Lupus erythematosus can be treated by administering therapeutic amounts of &Dgr;5-androstene-3&bgr;-ol-7,17-dione and metabolizable precursors thereof, such as &Dgr;5-androstene-3&bgr;-acetoxy-7,17-dione, which are readily metabolized in vivo to &Dgr;5-androstene-3&bgr;-ol-7,17-dione but are not appreciably metabolizable in vivo to androgens, estrogens or dehydroepiandrosterone. Such treatment can be prophylactic, ameliorative or curative in nature.
    Type: Application
    Filed: March 22, 2002
    Publication date: October 31, 2002
    Inventors: Henry A. Lardy, Charles E. Weeks
  • Process for effecting allylic oxidation using dicarboxylic acid imides and chromium reagents
    Patent number: 6384251
    Abstract: A procedure for oxidizing organic compounds having allylic hydrogen atom(s) involving the steps of reactively contacting the organic compound with a combination of an N-hydroxy dicarboxylic acid imide and a chromium-containing oxidant. The reaction can conveniently be conducted under ambient temperature and pressure conditions, and is conveniently conducted in a co-solvent system of water and organic solvent(s).
    Type: Grant
    Filed: November 8, 1999
    Date of Patent: May 7, 2002
    Assignee: Humanetics Corporation
    Inventors: Padma Marwah, Henry A. Lardy
  • Use of delta5-androstene-3beta-ol-7, 17-dione in the treatment of lupus erythematosus
    Patent number: 6372732
    Abstract: Lupus erythematosus can be treated by administering therapeutic amounts of delta-5-androstene-3-beta-ol-7,17-dione and its metabolizable precursors, which are not appreciably metabolized in vivo to androgens, estrogens or dehydroepiandrosterone. Such treatment can be prophylactic, ameliorative or curative in nature.
    Type: Grant
    Filed: December 4, 2000
    Date of Patent: April 16, 2002
    Assignee: Humanetics Corporation
    Inventors: Henry A. Lardy, Charles E. Weeks
  • Process for allylic oxidation using metal hypochlorite and alkyl hydroperoxide
    Patent number: 6274746
    Abstract: The present invention is directed to a process for effecting the allylic oxidation of an allylic compound having at least two allylic hydrogen atoms on the same carbon atom into corresponding &agr;,&bgr;-unsaturated carbonyl compound, using a combination of a metal hypochlorite and an alkyl hydroperoxide in a mixture of suitable conventional organic solvent(s) and/or water at a temperature of between about −5° C. to +25° C.
    Type: Grant
    Filed: August 30, 2000
    Date of Patent: August 14, 2001
    Inventors: Padma Marwah, Henry A. Lardy, Ashok Kumar Marwah
  • Memory enhancement by the administration of .DELTA.5-androstene-3.beta.-ol-7,17-dione and 3.beta. esters thereof
    Patent number: 6153606
    Abstract: The memory of a healthy mammal and the memory of a mammal with age impaired memory can be improved by administering an effective amount of .DELTA.5-Androstene-3.beta.-ol-7,17-dione and 3.beta. esters thereof.
    Type: Grant
    Filed: October 16, 1998
    Date of Patent: November 28, 2000
    Assignee: Humanetics Corporation
    Inventors: Henry A. Lardy, Jennifer Y. Shi
  • Process for effecting allylic oxidation
    Patent number: 6111118
    Abstract: A procedure for oxidizing organic compounds having allylic hydrogen atom(s) involving the steps of reactively contacting the organic compound with a combination of a periodic acid or metal periodate and an alkyl hydroperoxide under conditions of normal as well as elevated pressure of a suitable gas like air. The reaction can conveniently be conducted at temperatures between about 0-65.degree. C. in a cosolvent system of water and organic solvent(s).
    Type: Grant
    Filed: January 11, 1999
    Date of Patent: August 29, 2000
    Assignee: Humanetics Corporation
    Inventors: Padma Marwah, Henry A. Lardy
  • Use of .DELTA.5 androstenes in the treatment of HIV wasting syndrome
    Patent number: 5885977
    Abstract: HIV-related weight loss, HIV-related cachexia and HIV-related wasting syndrome can be treated by administering therapeutic amounts of the steroid .DELTA.5-androstene-3.beta.-ol-7,17 dione and metabolizable precursors thereof, such as .DELTA.5-androstene-3.beta.-acetoxy-7,17 dione, which are readily metabolized in vivo to .DELTA.5 androstene-3.beta.-ol-7,17 dione. Such treatment can be prophylactic, modulatory, ameliorative or curative in nature.
    Type: Grant
    Filed: January 15, 1997
    Date of Patent: March 23, 1999
    Assignee: Humanetics Corporation
    Inventors: C. David Pauza, Henry A. Lardy
  • Process for effecting allylic oxidation
    Patent number: 5869709
    Abstract: A procedure for oxidizing organic compounds having allylic hydrogen atom(s) involving the steps of reactively contacting the organic compound with a combination of an alkali metal periodate and an alkyl hydroperoxide. The reaction can conveniently be conducted under ambient temperature and pressure conditions, and is conveniently conducted in a cosolvent system of water and organic solvent(s).
    Type: Grant
    Filed: May 7, 1997
    Date of Patent: February 9, 1999
    Assignee: Humanetics Corporation
    Inventors: Padma Marwah, Henry A. Lardy
  • Use of dehydroepeiandrosterone-3-carboxylates to control body weight
    Patent number: 5807848
    Abstract: Method of prophylactically averting weight gain, promoting weight loss and treating obesity with a family of thermogenic steroids. Such steroids include substantially pure .DELTA.5 Androstene-17-ones having an ester of a saturated, unbranched C.sub.2-24 monocarboxylic acid attached at the 3.beta.-position of the base steroid ring.
    Type: Grant
    Filed: December 16, 1996
    Date of Patent: September 15, 1998
    Assignee: Humanetics Corporation
    Inventor: Henry A. Lardy
  • Treatment of alzheimer's disease and modulation of immune system with .DELTA.5-androstenes
    Patent number: 5707983
    Abstract: Alzheimer's disease and immune deficiency disorders may be effectively treated by administering a .DELTA.5-Androstene-3.beta.-ol-17-one having a C.sub.7 substituent selected from the group consisting of oxo, hydroxy and groups convertible thereto by hydrolysis by administering a therapeutic amount of a .DELTA.5-Androstene-3.beta.-ol-17-one having a C.sub.7 substituent selected from the group consisting of oxo, hydroxy and groups convertible thereto by hydrolysis.
    Type: Grant
    Filed: February 24, 1997
    Date of Patent: January 13, 1998
    Assignee: Humanetics Corporation
    Inventor: Henry A. Lardy
  • UP-regulation of immune system with .DELTA. 5-Androstenes
    Patent number: 5641766
    Abstract: Alzheimer's disease and immune deficiency disorders may be effectively treated by administering a .DELTA.5-Androstene-3.beta.-ol-17-one having a C.sub.7 substituent selected from the group consisting of oxo, hydroxy and groups convertible thereto by hydrolysis by administering a therapeutic amount of a .DELTA.5-Androstene-3.beta.-ol-17-one having a C.sub.7 substituent selected from the group consisting of oxo, hydroxy and groups convertible thereto by hydrolysis.
    Type: Grant
    Filed: September 13, 1995
    Date of Patent: June 24, 1997
    Assignee: Humanetics Corporation
    Inventor: Henry A. Lardy
  • Treatment of immune system with .DELTA.5-androstenes
    Patent number: 5585371
    Abstract: Immune system response may be enhanced by administering a .DELTA.5-Androstene-3.beta.-ol-17-one having a C.sub.7 substituent selected from the group consisting of oxo, hydroxy and groups convertible thereto by hydrolysis.
    Type: Grant
    Filed: February 2, 1994
    Date of Patent: December 17, 1996
    Assignee: Humanetics Corporation
    Inventor: Henry A. Lardy
  • .DELTA.5-androstenes useful for promoting weight maintenance or weight loss and treatment process
    Patent number: 5506223
    Abstract: A method for promoting weight control by treating a subject with a therapeutic amount of one of the .DELTA.5-androstenes listed below to stimulate weight control without affecting appetite or inducing the synthesis of sex hormones..DELTA.5-Androstenes providing the desired biological activities include:.DELTA.5-Androstene-3.beta.,7.alpha.-diol-17-one (1).DELTA.5-Androstene-3.beta.-ol-7,17-dione (2).DELTA.5-Androstene-3.beta.,7.alpha.,17.beta.-triol (3).DELTA.5-Androstene-3.beta.,17.beta.-diol-7-one (4).DELTA.5-Androstene-3.beta.-acetoxy-7,16,17-trione (5).DELTA.5-Androstene-3.beta.,16.alpha.-dihydroxy-7,17-dione (6).DELTA.5-Androstene-3.beta.-propionoxy-16.beta.-acetoxy-7,17-dione (7).DELTA.5-Androstene-3.beta.,7.alpha.,17.beta.-triol-16-one (8).DELTA.5-Androstene-3.beta.,17.beta.-diol-7,16-dione (9).DELTA.5-Androstene-3.beta.,16.alpha.,17.beta.-triol-7-one (10)and derivatives thereof wherein one or more of the hydroxyl or keto substituents is a group convertible thereto by hydrolysis.
    Type: Grant
    Filed: October 24, 1994
    Date of Patent: April 9, 1996
    Assignee: Humanetics Corporation
    Inventors: Henry A. Lardy, Ieva L. Reich, Yong Wei
  • .DELTA.5-androstenes useful for promoting weight maintenance or weight loss and treatment process
    Patent number: 5424463
    Abstract: A method for promoting weight control by treating a subject with a therapeutic amount of one of the .DELTA.5-androstenes listed below to stimulate weight control without affecting appetite or inducing the synthesis of sex hormones. .DELTA.5-Androstenes providing the desired biological activities include:.DELTA.5-Androstene-3.beta.,7.alpha.-diol-17-one.DELTA.5-Androstene-3.beta.-ol-7,17-dione.DELTA.5-Androstene-3.beta.,7.alpha.,17.beta.-triol.DELTA.5-Androstene-3.beta.,17.beta.-diol-7-one.DELTA.5-Androstene-3.beta.-acetoxy-7,16,17-trione.DELTA.5-Androstene-3.beta.,16.alpha.-dihydroxy-7,17-dione.DELTA.5-Androstene-3.alpha.-propionoxy-16.beta.-acetoxy-7,17-dione.DELTA.5-Androstene-3.beta.,7.alpha.,17.beta.-triol-16-one.DELTA.5-Androstene-3.beta.,17.beta.-diol-7,16-dione.DELTA.5-Androstene-3.beta.,16.alpha.,17.beta.-triol-7-one.
    Type: Grant
    Filed: October 24, 1994
    Date of Patent: June 13, 1995
    Assignee: Humanetics Corporation
    Inventors: Henry A. Lardy, Ieva L. Reich, Yong Wei
  • Treatment process for promoting weight loss employing a substituted .DELTA. 5
    Patent number: 5296481
    Abstract: A method for controlling weight gain or promoting weight loss which includes the step of treating a subject with an effective weight gain controlling or weight loss promoting amount of a substituted .DELTA.5-Androstene which is biologically effective for controlling weight gain or promoting weight loss and biologically ineffective for promoting the synthesis of sex hormones. Steroids believed to provide the desired weight control/weight loss characteristics include:.DELTA.5-Androstene-3.beta.,7.alpha.-diol-17-one.DELTA.5-Androstene-3.beta.-ol-7,17-dione.DELTA.5-Androstene-3.beta.,7.alpha.,17-triol.DELTA.5-Androstene-3.beta.,17.beta.-diol-7-oneand various derivatives thereof.
    Type: Grant
    Filed: April 10, 1992
    Date of Patent: March 22, 1994
    Assignee: Humanetics Corporation
    Inventors: Bruce E. Partridge, Henry A. Lardy
  • Modulation of immune system with .DELTA.5-androstenes
    Patent number: 5292730
    Abstract: Alzheimer's disease and immune deficiency disorders may be effectively treated by administering a .DELTA.5-Androstene-3.beta.-ol-17-one having a C.sub.7 substituent selected from the group consisting of oxo, hydroxy and groups convertible thereto by hydrolysis.by administering a therapeutic amount of a .DELTA.5-Androstene-3.beta.-ol-17-one having a C.sub.7 substituent selected from the group consisting of oxo, hydroxy and groups convertible thereto by hydrolysis.
    Type: Grant
    Filed: July 31, 1992
    Date of Patent: March 8, 1994
    Assignee: Humanetics Corporation
    Inventor: Henry A. Lardy